CCN2 requires TGF-β signalling to regulate CCAAT/enhancer binding proteins and inhibit fat cell differentiation

Area of Science:

• Cell Biology
• Molecular Biology
• Biochemistry

Background:

• Fat cell differentiation (FCD) is key for lipid storage and insulin sensitivity.
• Connective tissue growth factor (CCN2/CTGF) has been shown to inhibit FCD in vitro.
• The role of transforming growth factor-beta (TGF-β) in CCN2's effect on FCD requires clarification.

Purpose of the Study:

• To investigate whether CCN2's inhibition of FCD is dependent on TGF-β signaling.
• To elucidate the specific TGF-β pathway components involved in CCN2-mediated FCD inhibition.

Main Methods:

• NIH3T3-L1 cells were induced to differentiate and treated with TGF-β1, CCN2, and/or a TGF-β receptor blocker (SB431542).
• Gene expression of FCD markers (resistin, adiponectin) and transcription factors (C/EBPs, PPAR-γ) were analyzed.
• Protein levels and SMAD-3 phosphorylation were assessed to evaluate pathway activation.

Main Results:

• Both TGF-β1 and CCN2 significantly inhibited early FCD markers (C/EBP-β, -δ mRNA and protein).
• CCN2's inhibition of FCD markers and lipid accumulation was reversed by TGF-β receptor blockade and neutralizing antibodies.
• CCN2 and TGF-β treatments rapidly induced SMAD-3 phosphorylation, indicating pathway activation.

Conclusions:

• CCN2 exerts its inhibitory effects on fat cell differentiation through TGF-β-dependent pathways.
• Early effects on CCAAT/enhancer binding proteins (C/EBPs) are critical for CCN2's mechanism in FCD.
• This study reveals a novel link between CCN2, TGF-β signaling, and adipogenesis.